News

February 14, 2018
Oncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare Conference
February 1, 2018
Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)
January 29, 2018
Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market
January 25, 2018
Oncolytics Biotech(R) Named to the 2018 OTCQX Best 50
January 19, 2018
Oncolytics Biotech(R) Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
January 16, 2018
Oncolytics Biotech® Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
December 27, 2017
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
December 5, 2017
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer
December 4, 2017
Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit
November 30, 2017
Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Secret Link